ArticleNucleic acids research1994
Functional differences between the Oct2 transactivation domains determine the transactivation potential of individual Oct2 isoforms.
Article in Nucleic acids research, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Oct-2 transcription factor binding activity and expression up-regulation in rat cerebral ischaemia is associated with a diminution of neuronal damage in vitro.Neuromolecular medicine · 2014Article
- Oct2 and Obf1 as Facilitators of B:T Cell Collaboration during a Humoral Immune Response.Frontiers in immunology · 2014Article
- Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.Oncogene · 2006Article
- Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- The different alternatively spliced isoforms of the Oct-2 transcription factor repress the involucrin promoter in a cell type-specific manner.Molecular biology reports · 1998Article
- Adjacent proline residues in the inhibitory domain of the Oct-2 transcription factor play distinct functional roles.Nucleic acids research · 1998Article
- The carboxy-terminal transactivation domain of Oct-4 acquires cell specificity through the POU domain.Molecular and cellular biology · 1997Article
- CRISP-3, a protein with homology to plant defense proteins, is expressed in mouse B cells under the control of Oct2.Molecular and cellular biology · 1996Article
- Gene structure and characterization of the murine homologue of the B cell-specific transcriptional coactivator OBF-1.Nucleic acids research · 1996Article
- Transcriptional activation by Myc is under negative control by the transcription factor AP-2.The EMBO journal · 1995Article
- High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors.The EMBO journal · 1995Article
- Protein-DNA interactions during phenotypic differentiation.Molecular neurobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lymphocyte specific transcription factor Oct2 is involved in mediating the B-cell specific transcriptional activity of the octamer motif. Mutational analyses in the context of the complete Oct2 protein had indicated that Oct2 contains two transactivation domains. These two domains appeared to be redundant for activation from a promoter proximal position, whereas stimulation from a remote enhancer position specifically required the C-terminal transactivation domain and an additional B-cell restricted activity. We have generated fusion proteins between the DNA binding domain of the yeast Gal4 transcription factor and individual Oct2 protein domains to analyze their transactivation potential separately. We show that both N- and C-terminal domains can stimulate transcription from a promoter proximal position independently. However, only the C-terminal transactivation domain activates from a distance and it can only do so in B-cells. The C-terminal transactivation domain represents a composite transactivation domain. Whereas removal of just 9 aminoacids from the extreme C-terminus lead to a complete inactivation of this domain deletions from the other side resulted in a gradual loss of activity. We also characterized the transactivation potential of different N-terminal regions of Oct2 generated by alternative splicing. We show that the N-terminus of one of the isoforms, Oct2.3, contains a negative regulatory domain (NRD), which can inactivate the neighbouring glutamine-rich transactivation in cis. The presence of this NRD affects the overall phosphorylation state of the Oct2 protein. This result suggests that the mechanism of inactivation might involve differential protein phosphorylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.